AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell therapies business.

AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total ...

The most recent trading session ended with Astrazeneca (AZN) standing at $65.35, reflecting a +1.41% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily gain of ...

AstraZeneca also signed an AI-centered drug discovery pact with Illumina in October of last year, and in 2021, it gained access to Nvidia's newest supercomputer in the U.K. as part of a ...

Summary. AstraZeneca is acquiring Fusion Pharmaceuticals for up to $2.4 billion to expand its presence in the radiopharmaceuticals market. The acquisition includes Fusion's late-stage ...

U.K.-based AstraZeneca (AZN 1.71%) is now gearing up for the second time to develop a challenger to Novo Nordisk's (NVO 2.96%) Ozempic, its absurdly successful treatment for type 2 diabetes. If ...

AstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company tries to grab a slice of the booming weight-loss market and aims to almost double ...